Hepatocellular Carcinoma Clinical Trials in New York, New York

6 studies are recruiting for hepatocellular carcinoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

    This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in pa…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, New York, New York
    Locations
    219 in total
    Run by
    AstraZeneca

    See if you can join NCT06921785 on ClinicalTrials.gov

  2. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    New York Cancer & Blood Specialists, New York, New York
    Locations
    10 in total
    Run by
    Nammi Therapeutics Inc

    See if you can join NCT06582017 on ClinicalTrials.gov

  3. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 255132, New York, New York
    Locations
    54 in total
    Run by
    AbbVie

    See if you can join NCT06084481 on ClinicalTrials.gov

  4. Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

    A single institution, single arm, two-cohort feasibility trial to evaluate the combination of locoregional Y\^90 therapy with systemic atezolizumab and bevacizumab, in participants presenting with hepatocellular carcinoma (HCC) 1) within Milan Criteria (MC) with AFP ≥ 400 ng/ml as a means of bridge…

    Stage
    Phase 4
    Ages
    18 and older
    Site
    Icahn School of Medicine at Mount Sinai, New York, New York
    Run by
    Icahn School of Medicine at Mount Sinai

    See if you can join NCT07059494 on ClinicalTrials.gov

  5. A Study of ZW251 in Participants With Advanced Solid Tumors

    The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    25 in total
    Run by
    Zymeworks BC Inc.

    See if you can join NCT07164313 on ClinicalTrials.gov

  6. A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

    The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolera…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center - New York, New York, New York
    Locations
    21 in total
    Run by
    Tvardi Therapeutics, Incorporated

    See if you can join NCT05440708 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.